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Primary cardiac tumors of the heart are rare. The prevalence of
uch neoplasms has been reported to range from 0.001% to 0.03% in
ost-mortem series [1]. On the other hand, metastatic involvement
f the heart is approximately 30 times more prevalent than primary
ardiac tumors. Primary cardiac neoplasms include both benign and
alignant histological types. Approximately 75% of primary cardiac
umors are benign and nearly half of these are myxomas. The major-
ty of primary malignant tumors of the heart are sarcomas, most
ften vascular in origin [2]. Angiosarcoma is the most common,
hereas osteosarcoma and myxoﬁbrosarcoma are the least com-
on of the various primary cardiac sarcomas. Thus, the histological
ypes of cardiac tumors are varied, accordingly characterization of
ardiac tumors using imaging techniques has been challenging.
Recently, image resolution and tissue characterization of vari-
us imaging modalities have been developed, therefore, familiarity
ith certain imaging features could help to diagnose cardiac
umors. Up to now, transthoracic echocardiography has been the
ost widely used imaging modality for the evaluation of cardiac
asses. Echocardiography is the best imaging modality to depict
mall masses that arise from the cardiac valves because of high
esolution. In addition, it allows assessment of hemodynamic alter-
tion by cardiac tumors, such as valve obstruction and tamponade.
D echocardiography can provide the opportunity of true spa-
ial assessment of entire tumors (rather than individual slices of
umors) and help to understand the relationship between tumors
nd adjacent cardiac structures. However, although the use of
ransesophageal echocardiography overcomes the limited acous-
ic window of the transthoracic mode, visualization of extracardiac
xtension is suboptimal since the airways and lungs can be obsta-
les for imaging of the aortic arch, pulmonary arteries, and some
ystemic and pulmonary veins. On the other hand, multidetector
omputed tomography (MDCT) can provide anatomical informa-
ion without blind spots and be useful in staging of malignant
umors. The use of electrocardiogram-gated MDCT has better soft
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ize fatty content and calciﬁcations. A wide ﬁeld-of-view with MDCT
helps to assess the extent of a cardiac malignancy and helps to
detect metastatic lesions. However, MDCT also has disadvantages
including radiation exposure and need for nephrotoxic contrast
material. Streak artifacts can occur when the contrast material
remains in the right heart during image acquisition. Magnetic reso-
nance imaging (MRI) is useful for tissue characterization of cardiac
masses. High contrast resolution and multiplanar capability allow a
speciﬁc diagnosis and optimal evaluation of myocardial inﬁltration,
pericardial involvement, and extracardiac extension. The use of
MRI  allows characterization of a mass due to ﬁbromas and heman-
giomas. Homogeneity of a mass due to compact cellularity may
be characteristic of a lymphoma [3]. Acquisition of post-contrast
sequences enables better depiction of tumor vascularity and can be
used to deﬁne tumor borders. In addition, differentiation between
cardiac tumors and thrombi by MRI  can be helpful to avoid unnec-
essary surgical procedures. Disadvantages of the use of MRI  include
a long scan time and the inability to demonstrate calciﬁcation
and small masses, especially in cardiac valves due to limited spa-
tial resolution. MRI  is not available to the patients with non-MRI
compatible pacemaker and implantable cardioverter-deﬁbrillator
devices, and those with non-sinus rhythm and claustrophobia.
Thus, each imaging modality has different strengths and limita-
tions. Combination of echocardiography, MDCT, and MRI  could aid
differential diagnosis, and allow determination of the resectability
of tumors and planning for the reconstruction of cardiac chambers
in pre-surgical assessment.
Myxoﬁbrosarcoma is a tumor of mesenchymal origin that occurs
most commonly in the extremities of the elderly [2,4]. Tumors
typically arise in the lower and upper extremities, trunk, retroperi-
toneum, as well as the head and neck region. More than half of these
are located in dermal or subcutaneous tissues. Myxoﬁbrosarcoma
infrequently occurs in other tissues but has been reported to arise
in the tunica albuginea of the testis, cervix, vulva, breast, esopha-
gus, maxillary, and sphenoid sinuses, hypopharynx, intra-articular
region of the hip, tibia, mandible, external auditory canal, and pos-
sibly pancreas. Low-grade myxoﬁbrosarcoma tends to metastasize
locally, requiring wide surgical resection. Repeated local recurren-
ces with progressively poor differentiation may occur in such cases.
High-grade myxoﬁbrosarcoma also invade local and contiguous tis-
sues but are also associated with distant metastasis (lymph nodes,
lungs, brain, and bone). The cell origin of myxoﬁbrosarcoma is the
myoﬁbroblast. Some experts believe that this tumor is the myxoid
variant of malignant ﬁbrous histiocytoma [2,4].
vier Ltd. All rights reserved.
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Primary cardiac myxoﬁbrosarcoma rarely arises in the heart.
o our knowledge, the case reported by Iglesias et al. [5] is the
5th case since 1963 in the PubMed database [6–15]. Patients’ age
anged from 6 to 66 years (mean age 39.6 years), which is younger
han those with myxoﬁbrosarcoma in extracardiac organs (60.5
ears), and there were 6 males and 9 females. The most common
ymptom was dyspnea, which was similar to myxomas. Tumors
nvolved predominantly the left atrial cavities (10 cases), mitral
alve in 2 cases, right atrium in 1 case, and left ventricle in 1 case
information on 1 case was not available). Tumors may  be unicen-
ric or multicentric. Low-grade tumors invade local tissue including
alvular structures. High-grade tumors also invade locally, but
ay  also metastasize to contiguous and distant sites. Left atrial
yxoﬁbrosarcoma may  simulate left atrial myxoma in its clinical
resentation. The outcomes of the patients were unfavorable. Of all
atients, only 2 achieved complete recovery: a 66-year-old woman
fter tumor resection and radiation therapy [10] and a 6-year-old
irl after heart transplantation [14]. The remaining 13 patients died
r had a recurrence 3–50 months after diagnosis despite surgical
esection, radiation therapy, and chemotherapy. The case reported
y Iglesias et al. is surviving 46 months after diagnosis with only
ew symptoms fortunately [5].
At the current moment, cardiac myxoﬁbrosarcoma is difﬁcult
o differentiate from myxomas. Heterogeneity is a common fea-
ure of myxomas and myxoﬁbrosarcomas, and is characterized by
emorrhage, necrosis, cyst formation, ﬁbrosis, or calciﬁcation. Both
ypically have lobular contours. However, the prognoses of the two
umor types are quite different. Further improvement in imaging
echniques is required before myxoﬁbrosarcoma can be diagnosed
efore surgery.
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